Eribulin Improved Overall Survival In Patients With Her-2 Negative Metastatic Breast Cancer: Comparison To Bevacizumab Plus Paclitaxel.

e12035Background: Eribulin mesylate demonstrated to significant improvement in overall survival (OS) in patients with heavily pretreated, locally recurrent or metastatic breast cancer when compared to treatment of physician’s choice. On the other hand, Bevacizumab improved progression fee survival (PHS), but did not do OS. Thus, OS does not necessarily accord with PHS, and there was few clinical study that assess OS as primary endpoint. Methods: HER-2 negative metastatic breast cancer (MBC) patients who underwent chemotherapy of eribulin monotherapy or bevacizumab plus paclitaxel for first to fourth line chemotherapy in our department from November 1, 2011 to September 30, 2015 were reviewed. Kaplan-Meier method was utilized to estimate median OS and log-rank test was used to compare OS. The primary efficacy measure assessed OS, which was calculated as the time from the diagnosis of MBC until death from any case. Results: A total of 56 patients with MBC were assessed in this study (eribulin (E):29cases, b...